{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05561738",
            "orgStudyIdInfo": {
                "id": "STUDY22060104"
            },
            "organization": {
                "fullName": "University of Pittsburgh",
                "class": "OTHER"
            },
            "briefTitle": "Nicotinamide Riboside in Ulcerative Colitis",
            "officialTitle": "Nicotinamide Riboside in Ulcerative Colitis",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "nicotinamide-riboside-in-ulcerative-colitis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-13",
            "studyFirstSubmitQcDate": "2022-09-27",
            "studyFirstPostDateStruct": {
                "date": "2022-09-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Kevin Mollen",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "University of Pittsburgh"
            },
            "leadSponsor": {
                "name": "University of Pittsburgh",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Crohn's and Colitis Foundation",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).",
            "detailedDescription": "The investigators hypothesize that NR will alleviate mitochondrial dysfunction and restore metabolic homeostasis in the intestinal epithelium in pediatric patients with UC.\n\nThe purpose of the study are:\n\n1. To establish the feasibility of an Randomized Clinical Trial (RCT) investigating the effects of NR in pediatric patients with UC.\n2. To evaluate the effects of Nicotinamide adenine dinucleotide (NAD)+ repletion on intestinal epithelial mitochondrial structure and function in human UC patients. The investigators hypothesize that daily NR supplementation will restore NAD+ levels, enhancing Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1\u03b1) activity and mitochondrial structure/function."
        },
        "conditionsModule": {
            "conditions": [
                "Ulcerative Colitis"
            ],
            "keywords": [
                "NAD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Daily oral therapy with Nicotinamide Riboside Chloride (Niagen) + Standard Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Nicotinamide Riboside Chloride (Niagen) 75mg or 250mg capsules provided by ChromaDex, Inc. Dosing is recommended at 12.5mg/kg/day.\n\nThe dosing plan is as follows (in mg po qD):\n\n20-25 kg 250mg; 25-30 kg 325mg; 30-35 kg 400mg; 35-40 kg 475mg; 40-45 kg 500mg; 45-50 kg 575mg; 50-55 kg 650mg; 55-60 kg 725mg; 60-65 kg 750mg; 65-70 kg 825mg; \\>70 kg 900mg (max dosing).",
                    "interventionNames": [
                        "Dietary Supplement: Nicotinamide Riboside Chloride",
                        "Other: Standard of Care"
                    ]
                },
                {
                    "label": "Daily oral therapy with placebo + Standard Therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Placebo 75mg or 250mg capsules provided by ChromaDex, Inc. Dosing is recommended at 12.5mg/kg/day.\n\nThe dosing plan is as follows (in mg po qD):\n\n20-25 kg 250mg; 25-30 kg 325mg; 30-35 kg 400mg; 35-40 kg 475mg; 40-45 kg 500mg; 45-50 kg 575mg; 50-55 kg 650mg; 55-60 kg 725mg; 60-65 kg 750mg; 65-70 kg 825mg; \\>70 kg 900mg (max dosing).",
                    "interventionNames": [
                        "Dietary Supplement: Placebo",
                        "Other: Standard of Care"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIETARY_SUPPLEMENT",
                    "name": "Nicotinamide Riboside Chloride",
                    "description": "The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.",
                    "armGroupLabels": [
                        "Daily oral therapy with Nicotinamide Riboside Chloride (Niagen) + Standard Therapy"
                    ]
                },
                {
                    "type": "DIETARY_SUPPLEMENT",
                    "name": "Placebo",
                    "description": "The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.",
                    "armGroupLabels": [
                        "Daily oral therapy with placebo + Standard Therapy"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Standard of Care",
                    "description": "Standard of Care",
                    "armGroupLabels": [
                        "Daily oral therapy with Nicotinamide Riboside Chloride (Niagen) + Standard Therapy",
                        "Daily oral therapy with placebo + Standard Therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients screened",
                    "description": "The investigators will report the number of overall patients screened for enrollment.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Proportion of patients screened who meet inclusion/exclusion criteria",
                    "description": "The investigators will report the number of patients screened who meet inclusion/exclusion criteria.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Enrollment percentage",
                    "description": "The investigators will report the proportion of eligible patients who enroll in the study per month.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Completion percentage",
                    "description": "The investigators will report the proportion of enrolled subjects who complete the study.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Reasons for exclusion",
                    "description": "The investigators will report the reasons that patients are excluded from the study.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Dropout rate",
                    "description": "The investigators will report the percentage of subjects who drop out per month.",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Reasons for dropout",
                    "description": "The investigators will log reasons for dropout.",
                    "timeFrame": "2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Changes in mitochondrial structure from baseline to 6-12 months",
                    "description": "Subjects will undergo colonoscopic evaluation at enrollment and after 6-12 months of treatment (per standard treatment protocols). Investigators will perform a qualitative analysis of mitochondrial structure using scanning electron microscopy and/or immunofluorescence at both timepoints.",
                    "timeFrame": "Baseline 6-12 months"
                },
                {
                    "measure": "Changes in mitochondrial function from baseline to 6-12 months",
                    "description": "Subjects will undergo colonoscopic evaluation at enrollment and after 6-12 months of treatment (per standard treatment protocols). Investigators will evaluate mitochondrial function (Complex 1 and 2) via the Oroboros 2K Analyzer \\[oxygen consumption \\[(pmol/(s \u00d7 mL)/\u03bcg protein\\] at both timepoints.",
                    "timeFrame": "Baseline 6-12 months"
                },
                {
                    "measure": "Changes in the PGC1\u03b1-Sirt1 axis from baseline to 6-12 months",
                    "description": "Subjects will undergo colonoscopic evaluation at enrollment and after 6-12 months of treatment (per standard treatment protocols). PGC1\u03b1 and Sirt1 levels will be evaluated in tissue biopsies using western blot (qualitative analysis of protein levels) and qRT-PCR analysis (quantitative gene expression in fold change) at both timepoints.",
                    "timeFrame": "Baseline 6-12 months"
                },
                {
                    "measure": "Changes in cellular metabolism from baseline to 6-12 months",
                    "description": "Subjects will undergo colonoscopic evaluation at enrollment and after 6-12 months of treatment (per standard treatment protocols). An untargeted metabolomic analysis of the intestinal epithelium will be performed at these time points (fold change) at both timepoints.",
                    "timeFrame": "Baseline 6-12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pediatric patients (\u226418yo);\n* Diagnosis of mild to moderate ulcerative colitis as determined by Pediatric Ulcerative Colitis Activity Index (PUCAI) and endoscopic scoring (Mayo) at the time of colonoscopy;\n* Although the investigators will target newly diagnosed patients (therefore, treatment na\u00efve), patients with established disease will also be enrolled.\n\nExclusion Criteria:\n\n* Patients with acute severe ulcerative colitis;\n* Concurrent gastrointestinal infection (ie. Clostridium difficile, Cytomegalovirus, etc.);\n* A diagnosis of Crohn's disease;\n* Indeterminate colitis/IBD-U;\n* In general, patients that have been treated with steroids or antibiotics in the past three months. Patients on Biologic medications may be enrolled if their dose has been stable for at least three months. Final determination of eligibility will be at the discretion of the treating investigator. After the initiation of the study, subjects may receive any medication to treat their disease as dictated by their care providers;\n* Patients who have other chronic inflammatory/autoimmune disorders or prior malignancy;\n* Pregnant women (All women of childbearing age will be required to use contraception at the time of inclusion).\n* Patients with existing renal or hepatic dysfunction;\n* Per standard of care guidance, subjects with platelets \\<50,000 do not undergo endoscopy and, therefore, are not eligible.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Min Shi",
                    "role": "CONTACT",
                    "phone": "412-692-6272",
                    "email": "shim@upmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kevin Mollen",
                    "affiliation": "University of Pittsburgh",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "UPMC Children's Hospital of Pittsburgh",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Min Shi",
                            "role": "CONTACT",
                            "email": "shim@upmc.edu"
                        },
                        {
                            "name": "Kevin P Mollen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "26484345",
                    "type": "BACKGROUND",
                    "citation": "Novak EA, Mollen KP. Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol. 2015 Oct 1;3:62. doi: 10.3389/fcell.2015.00062. eCollection 2015."
                },
                {
                    "pmid": "26969166",
                    "type": "BACKGROUND",
                    "citation": "Cunningham KE, Vincent G, Sodhi CP, Novak EA, Ranganathan S, Egan CE, Stolz DB, Rogers MB, Firek B, Morowitz MJ, Gittes GK, Zuckerbraun BS, Hackam DJ, Mollen KP. Peroxisome Proliferator-activated Receptor-gamma Coactivator 1-alpha (PGC1alpha) Protects against Experimental Murine Colitis. J Biol Chem. 2016 May 6;291(19):10184-200. doi: 10.1074/jbc.M115.688812. Epub 2016 Mar 11."
                },
                {
                    "pmid": "30604764",
                    "type": "BACKGROUND",
                    "citation": "Haberman Y, Karns R, Dexheimer PJ, Schirmer M, Somekh J, Jurickova I, Braun T, Novak E, Bauman L, Collins MH, Mo A, Rosen MJ, Bonkowski E, Gotman N, Marquis A, Nistel M, Rufo PA, Baker SS, Sauer CG, Markowitz J, Pfefferkorn MD, Rosh JR, Boyle BM, Mack DR, Baldassano RN, Shah S, Leleiko NS, Heyman MB, Grifiths AM, Patel AS, Noe JD, Aronow BJ, Kugathasan S, Walters TD, Gibson G, Thomas SD, Mollen K, Shen-Orr S, Huttenhower C, Xavier RJ, Hyams JS, Denson LA. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019 Jan 3;10(1):38. doi: 10.1038/s41467-018-07841-3."
                },
                {
                    "pmid": "26912654",
                    "type": "BACKGROUND",
                    "citation": "Larmonier CB, Shehab KW, Laubitz D, Jamwal DR, Ghishan FK, Kiela PR. Transcriptional Reprogramming and Resistance to Colonic Mucosal Injury in Poly(ADP-ribose) Polymerase 1 (PARP1)-deficient Mice. J Biol Chem. 2016 Apr 22;291(17):8918-30. doi: 10.1074/jbc.M116.714386. Epub 2016 Feb 24."
                },
                {
                    "pmid": "26788256",
                    "type": "BACKGROUND",
                    "citation": "Santos L, Escande C, Denicola A. Potential Modulation of Sirtuins by Oxidative Stress. Oxid Med Cell Longev. 2016;2016:9831825. doi: 10.1155/2016/9831825. Epub 2015 Dec 14."
                },
                {
                    "pmid": "28877980",
                    "type": "BACKGROUND",
                    "citation": "Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, Wieser V, Pfister A, Moser P, Hermann-Kleiter N, Baier G, Oberacher H, Tilg H, Moschen AR. NAD metabolism fuels human and mouse intestinal inflammation. Gut. 2018 Oct;67(10):1813-1823. doi: 10.1136/gutjnl-2017-314241. Epub 2017 Sep 6."
                },
                {
                    "pmid": "32486488",
                    "type": "BACKGROUND",
                    "citation": "Mehmel M, Jovanovic N, Spitz U. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Nutrients. 2020 May 31;12(6):1616. doi: 10.3390/nu12061616."
                },
                {
                    "pmid": "27721479",
                    "type": "BACKGROUND",
                    "citation": "Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016 Oct 10;7:12948. doi: 10.1038/ncomms12948."
                },
                {
                    "pmid": "31820774",
                    "type": "BACKGROUND",
                    "citation": "Jiang Y , Liu Y , Gao M , Xue M , Wang Z , Liang H . Nicotinamide riboside alleviates alcohol-induced depression-like behaviours in C57BL/6J mice by altering the intestinal microbiota associated with microglial activation and BDNF expression. Food Funct. 2020 Jan 29;11(1):378-391. doi: 10.1039/c9fo01780a."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "De-identified data and samples may be shared with the funding agent, other researchers or federal repositories in the future under and approved agreement.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "CSR"
            ],
            "timeFrame": "6 months after publication of the results of the study. Date will be available for 1 year.",
            "accessCriteria": "Prior to any sharing of any data, the research data/documents will be coded and all subject identifiers will be completely removed. Only the PI and co-investigators will have access to the coding. All others will have access to the completely deidentified data only.\n\nA data use agreement will be obtained and finalized prior to any of the data leaving the institution, and prior to any access by outside entities."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003092",
                    "term": "Colitis"
                },
                {
                    "id": "D000003093",
                    "term": "Colitis, Ulcerative"
                },
                {
                    "id": "D000014456",
                    "term": "Ulcer"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005759",
                    "term": "Gastroenteritis"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000015212",
                    "term": "Inflammatory Bowel Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17206",
                    "name": "Ulcer",
                    "asFound": "Ulcerative",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6320",
                    "name": "Colitis",
                    "asFound": "Colitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6321",
                    "name": "Colitis, Ulcerative",
                    "asFound": "Ulcerative Colitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8875",
                    "name": "Gastroenteritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17917",
                    "name": "Inflammatory Bowel Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009536",
                    "term": "Niacinamide"
                },
                {
                    "id": "D000009525",
                    "term": "Niacin"
                },
                {
                    "id": "D000009539",
                    "term": "Nicotinic Acids"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014803",
                    "term": "Vitamin B Complex"
                },
                {
                    "id": "D000014815",
                    "term": "Vitamins"
                },
                {
                    "id": "D000018977",
                    "term": "Micronutrients"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000960",
                    "term": "Hypolipidemic Agents"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000057847",
                    "term": "Lipid Regulating Agents"
                },
                {
                    "id": "D000014665",
                    "term": "Vasodilator Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12476",
                    "name": "Niacinamide",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12465",
                    "name": "Niacin",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12479",
                    "name": "Nicotinic Acids",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17558",
                    "name": "Vitamins",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M21009",
                    "name": "Micronutrients",
                    "relevance": "LOW"
                },
                {
                    "id": "M16885",
                    "name": "Trace Elements",
                    "relevance": "LOW"
                },
                {
                    "id": "M4278",
                    "name": "Hypolipidemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M28883",
                    "name": "Lipid Regulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17412",
                    "name": "Vasodilator Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "T455",
                    "name": "Nicotinamide",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "T453",
                    "name": "Niacin",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "T454",
                    "name": "Niacinamide",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "T456",
                    "name": "Nicotinic Acid",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "T471",
                    "name": "Vitamin B3",
                    "asFound": "Chemoradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}